presentation.mkdn 15 KB

123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444
  1. ---
  2. title: Bioinformatic analysis of complex, high-throughput genomic and epigenomic data in the context of $\mathsf{CD4}^{+}$ T-cell differentiation and diagnosis and treatment of transplant rejection
  3. author: |
  4. Ryan C. Thompson \
  5. Su Lab \
  6. The Scripps Research Institute
  7. date: October 24, 2019
  8. theme: Boadilla
  9. aspectratio: 169
  10. fontsize: 14pt
  11. ---
  12. ## Organ transplants are a life-saving treatment
  13. ::: incremental
  14. * 36,528 transplants performed in the USA in 2018[^organdonor]
  15. * 100 transplants every day!
  16. * Over 113,000 people on the national transplant waiting list as of
  17. July 2019
  18. :::
  19. [^organdonor]: [organdonor.gov](https://www.organdonor.gov/statistics-stories/statistics.html)
  20. ## Organ donation statistics for the USA in 2018[^organdonor]
  21. \centering
  22. ![](graphics/presentation/transplants-organ-CROP.pdf)
  23. ## Types of grafts
  24. A graft is categorized based on the relationship between donor and recipient:
  25. . . .
  26. ::: incremental
  27. * **Autograft:** Donor and recipient are the *same individual*
  28. * **Allograft:** Donor and recipient are *different individuals* of
  29. the *same species*
  30. * **Xenograft:** Donor and recipient are *different species*
  31. :::
  32. ## Allograft rejection is a major long-term problem
  33. ![Kidney allograft survival rates in children by transplant year[^kim-marks]](graphics/presentation/kidney-graft-survival.png){ height=65% }
  34. [^kim-marks]:[ Kim & Marks. "Long-term outcomes of children after solid organ transplantation". In: Clinics (2014)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884158/?report=classic)
  35. ## Graft rejection is an adaptive immune response
  36. <!-- TODO: Need a graphic for this -->
  37. ::: incremental
  38. * The host's adaptive immune system identifies and attacks cells
  39. bearing non-self antigens
  40. * An allograft contains differnet genetic variants from the host,
  41. resulting in protein-coding differences
  42. * Left unchecked, the host immune system eventually notices these
  43. alloantigens and begins attacking (rejecting) the graft
  44. * Rejection is the major long-term threat to organ allografts
  45. :::
  46. ## Rejection is treated with immune suppressive drugs
  47. <!-- TODO: Need a graphic, or maybe a table of common drugs +
  48. mechanisms, or a diagram for periodic checking. -->
  49. ::: incremental
  50. * To prevent rejection, a graft recipient must take immune suppressive
  51. drugs for the rest of their life
  52. * The graft is periodically checked for signs of rejection, and immune
  53. suppression dosage is adjusted accordingly
  54. * Immune suppression is a delicate balance: too much leads to immune
  55. compromise; too little leads to rejection.
  56. :::
  57. ## My thesis topics
  58. ### Topic 1: Immune memory
  59. Genome-wide epigenetic analysis of H3K4 and H3K27 methylation in naïve
  60. and memory $\mathsf{CD4}^{+}$ T-cell activation
  61. ### Topic 2: Diagnostics for rejection
  62. Improving array-based diagnostics for transplant rejection by
  63. optimizing data preprocessing
  64. ### Topic 3: Blood profiling during treatment
  65. Globin-blocking for more effective blood RNA-seq analysis in primate
  66. animal model for experimental graft rejection treatment
  67. ## Today's focus
  68. ### \Large Topic 1: Immune memory
  69. \Large
  70. Genome-wide epigenetic analysis of H3K4 and H3K27 methylation in naïve
  71. and memory $\mathsf{CD4}^{+}$ T-cell activation
  72. ## Memory cells: faster, stronger, and more independent
  73. ![Naïve and memory T-cell responses to activation](graphics/presentation/T-cells-A-SVG.png)
  74. ## Memory cells: faster, stronger, and more independent
  75. ![Naïve and memory T-cell responses to activation](graphics/presentation/T-cells-B-SVG.png)
  76. ## Memory cells: faster, stronger, and more independent
  77. ![Naïve and memory T-cell responses to activation](graphics/presentation/T-cells-C-SVG.png)
  78. ## Memory cells: faster, stronger, and more independent
  79. ![Naïve and memory T-cell responses to activation](graphics/presentation/T-cells-D-SVG.png)
  80. ## Memory cells are a problem for immune suppression
  81. <!-- Need graphics? Or maybe just mark this slide as speaker notes for the previous one -->
  82. \large
  83. Compared to naïve cells, memory cells:
  84. \normalsize
  85. * respond to a lower antigen concentration
  86. * respond more strongly at any given antigen concentration
  87. * require less co-stimulation
  88. * are somewhat independent of some types of co-stimulation required by
  89. naïve cells
  90. * evolve over time to respond even more strongly to their antigen
  91. ## Memory cells are a problem for immune suppression
  92. \large
  93. Result:
  94. \normalsize
  95. * Memory cells require progressively higher doses of immune suppresive
  96. drugs
  97. * Dosage cannot be increased indefinitely without compromising the
  98. immune system's ability to fight infection
  99. ## We need a better understanding of immune memory
  100. * Cell surface markers of naïve and memory $\mathsf{CD4}^{+}$ T-cells
  101. are fairly well-characterized
  102. * But internal mechanisms that allow memory cells to respond
  103. differently to the same stimulus (antigen presentation) are not
  104. well-understood
  105. . . .
  106. * A reasonable hypothesis is that some of these mechanisms are
  107. epigenetic: using histone marks or DNA methylation to regulate the
  108. expression of certain genes
  109. * We can test this hypothesis by measuring gene expression (using
  110. RNA-seq) and histone methylation (using ChIP-seq) in naïve and
  111. memory T-cells before and after activation
  112. ## Experimental design
  113. * Separately isolate naïve and memory $\mathsf{CD4}^{+}$ T-cells from
  114. 4 donors
  115. * Activate with CD3/CD28 beads
  116. * Take samples at 4 time points: Day 0 (pre-activation), Day 1 (early
  117. activation), Day 5 (peak activation), and Day 14 (post-activation)
  118. * Do RNA-seq + ChIP-seq for 3 histone marks (H3K4me2, H3K4me3, &
  119. H3K27me3) for each sample.
  120. Data generated by Sarah Lamere, published in GEO as
  121. [GSE73214](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73214)
  122. ## A few intermediate analysis steps are required
  123. ![Flowchart of workflow for data analysis](graphics/CD4-csaw/rulegraphs/rulegraph-all-RASTER100.png)
  124. ## Histone modifications occur on consecutive histones
  125. ![ChIP-seq coverage in IL2 gene[^lamerethesis]](graphics/presentation/LaMere-thesis-fig3.9-SVG-CROP.png){ height=65% }
  126. [^lamerethesis]: Sarah LaMere. "Dynamic epigenetic regulation of CD4 T cell activation and memory formation". PhD thesis. TSRI, 2015.
  127. ## Histone modifications occur on consecutive histones
  128. ![Strand cross-correlation plots](graphics/presentation/CCF-plots-A-SVG.png)
  129. ## Histone modifications occur on consecutive histones
  130. ![Strand cross-correlation plots](graphics/presentation/CCF-plots-B-SVG.png)
  131. ## Histone modifications occur on consecutive histones
  132. ![Strand cross-correlation plots](graphics/presentation/CCF-plots-C-SVG.png)
  133. ## SICER identifies enriched regions across the genome
  134. ![Finding "islands" of coverage with SICER[^sicer]](graphics/presentation/SICER-fig1-SVG.png)
  135. [^sicer]: [Zang et al. “A clustering approach for identification of enriched domains from histone modification ChIP-Seq data”. In: Bioinformatics 25.15 (2009)](https://doi.org/10.1093/bioinformatics/btp340)
  136. ## IDR identifies *reproducible* enriched regions
  137. ![Example irreproducible discovery rate[^idr] score consistency plot](graphics/presentation/IDR-example-CROP-RASTER.png){ height=65% }
  138. [^idr]: [Li et al. “Measuring reproducibility of high-throughput experiments”. In: AOAS (2011)](https://doi.org/10.1214/11-AOAS466)
  139. ## Finding enriched regions across the genome
  140. ![Peak-calling summary statistics](graphics/presentation/RCT-thesis-table2.2-SVG-CROP.png)
  141. ## Each histone mark has an "effective promoter radius"
  142. ![Enrichment of peaks near promoters](graphics/CD4-csaw/Promoter-Peak-Distance-Profile-PAGE1-CROP.pdf)
  143. ## Peaks in promoters correlate with gene expression
  144. ![Expression distributions of genes with and without promoter peaks](graphics/presentation/FPKM-by-Peak-Violin-Plots-A-SVG.png)
  145. ## Peaks in promoters correlate with gene expression
  146. ![Expression distributions of genes with and without promoter peaks](graphics/presentation/FPKM-by-Peak-Violin-Plots-B-SVG.png)
  147. ## Peaks in promoters correlate with gene expression
  148. ![Expression distributions of genes with and without promoter peaks](graphics/presentation/FPKM-by-Peak-Violin-Plots-C-SVG.png)
  149. ## Peaks in promoters correlate with gene expression
  150. ![Expression distributions of genes with and without promoter peaks](graphics/presentation/FPKM-by-Peak-Violin-Plots-D-SVG.png)
  151. ## Peaks in promoters correlate with gene expression
  152. ![Expression distributions of genes with and without promoter peaks](graphics/presentation/FPKM-by-Peak-Violin-Plots-Z-SVG.png)
  153. ## The story so far
  154. <!-- TODO: Left column: text; right column: flip through relevant image -->
  155. * H3K4me2, H3K4me3, and H3K27me3 occur on many consecutive histones in
  156. broad regions across the genome
  157. * These enriched regions occur more commonly within a certain radius
  158. of gene promoters
  159. * This "effective promoter radius" is consistent across all samples
  160. for a given histone mark, but differs between histone marks
  161. * Presence or absence of a peak within this radius is correlated with
  162. gene expression
  163. . . .
  164. Next: Does the position of a histone modification within a gene
  165. promoter matter to that gene's expression, or is it merely the
  166. presence or absence anywhere within the promoter?
  167. ## H3K4me2 promoter neighborhood K-means clusters
  168. ![Cluster means for H3K4me2](graphics/CD4-csaw/ChIP-seq/H3K4me2-neighborhood-clusters-CROP.png)
  169. ## H3K4me2 promoter neighborhood cluster PCA
  170. ::::: {.columns}
  171. ::: {.column width="50%"}
  172. ![Cluster means for H3K4me2](graphics/CD4-csaw/ChIP-seq/H3K4me2-neighborhood-clusters-CROP.png)
  173. :::
  174. ::: {.column width="50%"}
  175. ![PCA plot of promoters](graphics/CD4-csaw/ChIP-seq/H3K4me2-neighborhood-PCA-CROP.png)
  176. :::
  177. :::::
  178. ## H3K4me2 promoter neighborhood cluster expression
  179. ::::: {.columns}
  180. ::: {.column width="50%"}
  181. ![Cluster means for H3K4me2](graphics/CD4-csaw/ChIP-seq/H3K4me2-neighborhood-clusters-CROP.png)
  182. :::
  183. ::: {.column width="50%"}
  184. ![Cluster expression distributions](graphics/CD4-csaw/ChIP-seq/H3K4me2-neighborhood-expression-CROP-ROT90.png)
  185. :::
  186. :::::
  187. ## H3K4me3 promoter neighborhood cluster PCA
  188. ::::: {.columns}
  189. ::: {.column width="50%"}
  190. ![Cluster means for H3K4me3](graphics/CD4-csaw/ChIP-seq/H3K4me3-neighborhood-clusters-CROP.png)
  191. :::
  192. ::: {.column width="50%"}
  193. ![PCA plot of promoters](graphics/CD4-csaw/ChIP-seq/H3K4me3-neighborhood-PCA-CROP.png)
  194. :::
  195. :::::
  196. ## H3K4me3 promoter neighborhood cluster expression
  197. ::::: {.columns}
  198. ::: {.column width="50%"}
  199. ![Cluster means for H3K4me3](graphics/CD4-csaw/ChIP-seq/H3K4me3-neighborhood-clusters-CROP.png)
  200. :::
  201. ::: {.column width="50%"}
  202. ![Cluster expression distributions](graphics/CD4-csaw/ChIP-seq/H3K4me3-neighborhood-expression-CROP-ROT90.png)
  203. :::
  204. :::::
  205. ## H3K27me3 promoter neighborhood cluster PCA
  206. ::::: {.columns}
  207. ::: {.column width="50%"}
  208. ![Cluster means for H3K27me3](graphics/CD4-csaw/ChIP-seq/H3K27me3-neighborhood-clusters-CROP.png)
  209. :::
  210. ::: {.column width="50%"}
  211. ![PCA plot of promoters](graphics/CD4-csaw/ChIP-seq/H3K27me3-neighborhood-PCA-CROP.png)
  212. :::
  213. :::::
  214. ## H3K27me3 promoter neighborhood cluster expression
  215. ::::: {.columns}
  216. ::: {.column width="50%"}
  217. ![Cluster means for H3K27me3](graphics/CD4-csaw/ChIP-seq/H3K27me3-neighborhood-clusters-CROP.png)
  218. :::
  219. ::: {.column width="50%"}
  220. ![Cluster expression distributions](graphics/CD4-csaw/ChIP-seq/H3K27me3-neighborhood-expression-CROP-ROT90.png)
  221. :::
  222. :::::
  223. ## What have we learned?
  224. ### H3K4me2 & H3K4me3
  225. * Peak closer to promoter $\Rightarrow$ more likely gene is highly
  226. expressed
  227. * Slightly asymmetric in favor of peaks downstream of TSS
  228. . . .
  229. ### H3K27me3
  230. * Depletion of H3K27me3 at TSS associated with elevated gene
  231. expression
  232. * Enrichment of H3K27me3 upstream of TSS even more strongly associated
  233. with elevated expression
  234. * Other coverage profiles not associated with elevated expression
  235. ## Differential modification disappears by Day 14
  236. ![Differential modification between naïve and memory samples at each time point](graphics/presentation/RCT-thesis-table2.4-A-SVG-CROP.png)
  237. ## Differential modification disappears by Day 14
  238. ![Differential modification between naïve and memory samples at each time point](graphics/presentation/RCT-thesis-table2.4-B-SVG-CROP.png)
  239. ## Convergence at Day 14 H3K4me2
  240. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me2-promoter-PCA-group-CROP.png)
  241. ## Convergence at Day 14 H3K4me3
  242. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me3-promoter-PCA-group-CROP.png)
  243. ## Convergence at Day 14 H3K27me3
  244. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K27me3-promoter-PCA-group-CROP.png)
  245. ## Convergence at Day 14 RNA-seq (PC 2 & 3)
  246. ![(Insert figure legend)](graphics/CD4-csaw/RNA-seq/PCA-final-23-CROP.png)
  247. ## MOFA identifies shared variation across all 4 data sets
  248. ![(Insert figure legend)](graphics/presentation/MOFA-varExplained-matrix-A-CROP.png)
  249. ## MOFA identifies shared variation across all 4 data sets
  250. ![(Insert figure legend)](graphics/presentation/MOFA-varExplained-matrix-B-CROP.png)
  251. ## MOFA shared variation captures convergence pattern
  252. ![(Insert figure legend)](graphics/CD4-csaw/MOFA-LF-scatter-small.png)
  253. ## What have we learned?
  254. * Almost no differential modification observed between naïve and
  255. memory at Day 14, despite plenty of differential modification at
  256. earlier time points.
  257. * RNA-seq data and all 3 histone marks' ChIP-seq data all show
  258. "convergence" between naïve and memory by Day 14 in the first 2 or 3
  259. principal coordinates.
  260. * MOFA captures this convergence pattern in one of the latent factors,
  261. indicating that this is a shared pattern across all 4 data sets.
  262. <!-- ## Slide -->
  263. <!-- ![(Insert figure legend)](graphics/CD4-csaw/LaMere2016_fig8.pdf) -->
  264. ## Takeaway 1: Each histone mark has an "effective promoter radius"
  265. * H3K4me2, H3K4me3, and H3K27me3 ChIP-seq reads are enriched in broad
  266. regions across the genome, representing areas where the histone
  267. modification is present
  268. * These enriched regions occur more commonly within a certain radius
  269. of gene promoters
  270. * This "effective promoter radius" is specific to each histone mark
  271. * Presence or absence of a peak within this radius is correlated with
  272. gene expression
  273. ## Takeaway 2: Peak position within the promoter is important
  274. * H3K4me2 and H3K4me3 peaks are more strongly associated with elevated
  275. gene expression the closer they are to the TSS, with a slight bias
  276. toward downstream peaks.
  277. * H3K27me3 depletion at the TSS and enrichement upstream are both
  278. associated with elevated expression, while other patterns are not.
  279. * In all histone marks, position of modification within promoter
  280. appears to be an important factor in association with gene
  281. expression
  282. ## Takeaway 3: Expression & epigenetic state both converge at Day 14
  283. * At Day 14, almost no differential modification observed between
  284. naïve and memory cells
  285. * Naïve and memory converge visually in PCoA plots
  286. * Convergence is a shared pattern of variation across all 3 histone
  287. marks and gene expression
  288. * This is consistent with the hypothesis that the naïve cells have
  289. differentiated into a more memory-like phenotype by day 14.